Approved by the FDA earlier this year, the Alzheimer’s therapy lecanemab is an antibody that reduces the buildup in the brain of a sticky peptide called amyloid-beta (Aβ), which is thought to be a main driver of the disease. Dispensed in bimonthly infusions, lecanemab specifically targets protofibrils, the type of Aβ clumps thought to be the most neurotoxic. Studies have shown that lecanemab slows cognitive and functional decline in early-stage Alzheimer’s patients.